The FDA approved Eli Lilly's obesity pill on April 1, 2026, marking a pivotal moment in the obesity treatment landscape.
This approval positions Eli Lilly to enter a competitive market dominated by Novo Nordisk's Wegovy, which has already established a strong presence.
The introduction of Eli Lilly's product may influence treatment protocols and patient access, necessitating adjustments in healthcare infrastructure and resource allocation.
Updates
Update at 15:56 UTC on 2026-04-01
CNBC reported The FDA approval of Eli Lilly's GLP-1 pill Foundayo comes nearly three months after Novo Nordisk's oral version of Wegovy hit the market.
Sources: CNBC